Enabling Competitive Entry: The Role of Drug Delivery Device Design in the Biosimilars Market

International Pharmaceutical Industry (IPI) is a peer-reviewed journal providing the pharmaceutical and biopharmaceutical industry with coverage on key scientific, technology, regulatory and business topics. The publication has a global audience of professionals involved in outsourcing management for this sector.

With several original reference biologics coming off patent between 2018 and 2023, a significant window of opportunity for biosimiliar manufacturers has opened up. George I’ons, Head of Product Strategy and Insight at Owen Mumford Pharmaceutical Services, analyses the factors that will influence this new uptake and the impact this will have on the originial biologics market share.